 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acquisition enriches Kyowa Kirin's portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps to resource ongoing and future launches of...

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases

ORTX's total volume now sits at 372.3K. The +0.30% price change was insignificant, leaving IBM's price at $16.7...

The volume for Orchard Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 246% of the 65-Day Volume Moving Average

This is a Bullish indicator signaling ORTX's price could rise from here. Traders may explore going long the stock or buying call options...

Orchard Therapeutics (ORTX, $16.7) Moving Average Convergence Divergence (MACD) Histogram turned positive on January 23, 2024

This is a signal that ORTX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Orchard Therapeutics (ORTX, $16.54) RSI Indicator left the overbought zone on January 17, 2024

INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership team to help structure merged public...

INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors

Orchard Therapeutics (ORTX, $16.43) RSI Indicator left the overbought zone on January 02, 2024

Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.

Volume (M)	372,349.00
52-Wk High	$16.72
52-Wk Low	$4.24

ORTX Orchard Rx Ltd

About

Feed

News

Fundamentals